Michael Raab SEC Filing Summary

This filing details transactions made by Michael Raab, a director at AMICUS THERAPEUTICS, INC. (FOLD), on April 27, 2026. The transactions involved the disposal of 115,857 shares of Common Stock at $14.50 per share and the cancellation of various stock options. These actions were a result of the acquisition of AMICUS THERAPEUTICS, INC. by BioMarin Pharmaceutical Inc. The stock options were cancelled and converted into the right to receive a cash payment based on the difference between $14.50 and the exercise price per share. All reported stock options were fully vested at the time of the merger. Following these transactions, the post-transaction shares owned by Mr. Raab are zero.